CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges

Basit Öğe Kaydı
dc.authoridNourazarian, Alireza/0000-0003-2082-1335
dc.authorscopusid57216431373
dc.authorscopusid57434785100
dc.authorscopusid57221716042
dc.authorscopusid57193747964
dc.authorscopusid57203588534
dc.authorscopusid57435062900
dc.authorscopusid55565668500
dc.authorwosidNourazarian, Alireza/G-3873-2015
dc.contributor.authorShademan, Behrouz
dc.contributor.authorMasjedi, Sepideh
dc.contributor.authorKaramad, Vahidreza
dc.contributor.authorIsazadeh, Alireza
dc.contributor.authorSogutlu, Fatma
dc.contributor.authorRad, Mohammad Hosein Saeedi
dc.contributor.authorNourazarian, Alireza
dc.date.accessioned2023-01-12T19:50:30Z
dc.date.available2023-01-12T19:50:30Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractA novel gene editing tool, the Cas system, associated with the CRISPR system, is emerging as a potential method for genome modification. This simple method, based on the adaptive immune defense system of prokaryotes, has been developed and used in human cancer research. These technologies have tremendous therapeutic potential, especially in gene therapy, where a patient-specific mutation is genetically corrected to cure diseases that cannot be cured with conventional treatments. However, translating CRISPR/Cas9 into the clinic will be challenging, as we still need to improve the efficiency, specificity, and application of the technology. In this review, we will explain how CRISPR-Cas9 technology can treat cancer at the molecular level, focusing on ordination and the epigenome. We will also focus on the promise and shortcomings of this system to ensure its application in the treatment and prevention of cancer.en_US
dc.identifier.doi10.1007/s10528-022-10193-9
dc.identifier.endpage1470en_US
dc.identifier.issn0006-2928
dc.identifier.issn1573-4927
dc.identifier.issue5en_US
dc.identifier.pmid35092559en_US
dc.identifier.scopus2-s2.0-85123856430en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1446en_US
dc.identifier.urihttps://doi.org/10.1007/s10528-022-10193-9
dc.identifier.urihttps://hdl.handle.net/11454/76110
dc.identifier.volume60en_US
dc.identifier.wosWOS:000750323900002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer/Plenum Publishersen_US
dc.relation.ispartofBiochemical Geneticsen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCRISPRen_US
dc.subjectGene editingen_US
dc.subjectCancer treatmenten_US
dc.subjectSolid tumorsen_US
dc.subjectIn-Vivoen_US
dc.subjectColorectal-Canceren_US
dc.subjectLung-Canceren_US
dc.subjectChromosomal Translocationsen_US
dc.subjectTumor-Suppressoren_US
dc.subjectDna Methylationen_US
dc.subjectGene-Expressionen_US
dc.subjectHuman-Cellsen_US
dc.subjectGenomeen_US
dc.subjectCasen_US
dc.titleCRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challengesen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu